Novo Nordisk A S annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Stock-Based Compensation Growth & History (NVO)
Novo Nordisk A S's stock-based compensation was kr1.44B for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | kr1.44B | −kr854.0M | −37.31% |
| 2024 | 2024-12-31 | kr2.29B | kr140.0M | +6.51% |
| 2023 | 2023-12-31 | kr2.15B | kr610.0M | +39.64% |
| 2022 | 2022-12-31 | kr1.54B | kr499.0M | +47.98% |
| 2021 | 2021-12-31 | kr1.04B | kr217.0M | +26.37% |
| 2020 | 2020-12-31 | kr823.0M | kr460.0M | +126.72% |
| 2019 | 2019-12-31 | kr363.0M | — | — |
Novo Nordisk A S stock-based compensation trends
Over the last five fiscal years, Novo Nordisk A S's stock-based compensation increased from kr823.0M to kr1.44B, a change of kr612.0M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...